Disease-A-Month
Volume 53, Issue 2 , Pages 70-131 , February 2007

Attention Deficit Hyperactivity Disorder Across the Lifespan: The Child, Adolescent, and Adult

References 

  1. Lin-Dyken DC, Wolraich ML. Attention deficit hyperactivity disorder. In:  Greydanus DE,  Wolraich M editor. Behavioral Pediatrics. New York, NY: Springer-Verlag; 1992;p. 167–193
  2. Still G. The Coulstonian lectures on some abnormal physical conditions in children (Lecture 1). Lancet. 1902;1008–10121077-902, 1163-8
  3. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry. 2002;63(Suppl 12):29–35
  4. Clements SD. Minimal Brain Dysfunction in Children: Terminology and Identification. Washington DC: US Department of Health, Education, and Welfare; 1966;
  5. Ounsted C. The hyperkinetic syndrome in epileptic children. Lancet. 1955;II:3030–3311
  6. Dodson WW. Pharmacotherapy of adult ADHD. JCLP/In Session. 2005;61(5):589–606
  7. American Psychiatric Association. In: Diagnostic and Statistical Manual of Mental Disorders. (4th ed). Washington DC: American Psychiatric Association; 2000;p. 85–93
  8. Wood DR, Reimherr FW, Wender PG, et al. Diagnosis and treatment of minimum brain dysfunction in adults. Arch Gen Psychiatry. 1976;33:1456–1460
  9. Wilens TE, Spencer TJ, Biederman J. A review of pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Dis. 2002;5(4):189–202
  10. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry. 2003;2:104–113
  11. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716–723
  12. Katragadda S, Schubiner H. ADHD in children, adolescents, and adults. Prim Care Clin Office Pract. 2007;34(4):111
  13. Biederman J, Farone SV. Attention-deficit/hyperactivity disorder. Lancet. 2005;366:237–248
  14. Greydanus DE, Pratt HD. Attention deficit hyperactivity disorder. In:  Greydanus DE,  Pratt HD,  Patel DR editor. Behavioral Pediatrics. (2nd ed). Lincoln, NE: iUniverse Publishers; 2006;p. 107–142
  15. Pary R, Lewis S, Matuschka PR, et al. Attention deficit disorder in adults. Ann Clin Psychiatry. 2002;14(2):105–111
  16. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57:1215–1220
  17. Greydanus DE, Pratt HD. Attention deficit/hyperactivity disorder in adolescents. In:  Greydanus DE,  Patel DR,  Pratt HD editor. Essential Adolescent Medicine. New York, NY: McGraw-Hill Medical Publishers; 2006;p. 751–768
  18. Faraone SV, Khan SA. Candidate gene studies of attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl 8):13–20
  19. Wolraich ML, Felice ME, Drotar D. In: Impulsive/hyperactive or inattentive behaviors. The Classification of Child and Adolescent Mental Diagnosis in Primary Care: Diagnostic and Statistical Manual for Primary Care (DSM-PC) Child and Adolescent Version. Elk Grove Village, IL: American Academy of Pediatrics; 1996;p. 91–110
  20. Practice Management Information Corporation. In: International Classification of Diseases. (10th ed). Los Angeles, CA: Practice Management Information Corporation (PMIC); 2004;p. 223–224
  21. MacDonald E, Opipari-Arrigan L. Behavioral assessment. In:  Greydanus DE,  Patel DR,  Pratt HD editor. Behavioral Pediatrics. (2nd ed). Lincoln, NE: iUniverse Publishers; 2006;p. 651–669
  22. Larsen MA, Tentis E. Psychometric testing. In:  Greydanus DE,  Patel DR,  Pratt HD editor. Behavioral Pediatrics. (2nd ed). Lincoln, NE: iUniverse Publishers; 2006;p. 670–702
  23. National Institute of Mental Health (NIMH). Attention Deficit Hyperactivity Disorder. 2001;NIMH, NIH Publication No. 01-4589. Available at: http://www.nimh.nih.gov/publicat/helpchild.cfm.
  24. National Institute of Mental Health. NIMH Research on Treatment for Attention Deficit Hyperactivity Disorder (ADHD): The Multimodal Treatment Study: Questions and Answers. Washington DC: NIMH; 2000;Available at: http://www.nimh.nih.gov/events/mtaqa.cfm.
  25. National Institute of Health (NIH). Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder. NIH Consensus Statement Online 1998: Nov 16–18;16(2):1–37.
  26. Greydanus DE, Pratt HD, Sloane MA, et al. Attention-deficit/hyperactivity disorder in Children and adolescents: interventions for a complex costly clinical conundrum. Pediatr Clin North Am. 2003;50:1049–1092
  27. Whalen CK, Henker B. Therapies for hyperactive children: Comparisons, combinations, and compromises. J Consult Clin Psychol. 1991;59(1):126–137
  28. Pelham W, Fabriano GA. Behavior modification. Child Adolesc Psychiatr Clin N Am. 2000;9(3):671–688
  29. Pelham WE, Hoza B, Pillow DR, et al. Effects of methyphenidate and expectancy on children with ADHD: behavior, academic performance, and attributions in a summer treatment program and regular classroom settings. J Consult Clin Psychol. 2002;70:320–335
  30. Reuters Health. ADHD: Kids with Attention Problems More Likely to Wet Bed. Bethesda, MD: U.S. National Library of Medicine; 2002;Wednesday, October 23. Available at: http://www.nlm.nih.gov/medlineplus/news/fullstory10009.html.
  31. National Institute of Mental Health (NIMH). Attention Deficit Hyperactivity Disorder. 1999;NIMH. NIH Publication No. 96-3572. Available at: http://www.nimh.nih.gov/sciadvances/16.cfm.
  32. Hinshaw SP. Academic underachievement, attention deficits, and aggression: comorbidity and implications for intervention. J Consult Clin Psychol. 1992;60:893–903
  33. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry. 2001;40:147–158
  34. Wells KC, Epstein JN, Hinshaw SP, et al. Parenting and family stress treatment outcomes in attention deficit hyperactivity disorder (ADHD): an empirical analysis in the MTA study. J Abnorm Child Psychol. 2000;28:543–553
  35. Wells KC, Pelham WE, Kotkin RA, et al. Psychosocial treatment strategies in the MTA study: rationale, methods, and critical issues in design and implementation. J Abnorm Child Psychol. 2000;28:483–505
  36. Greydanus DE, Sloane MA, Rappley MD. Psychopharmacology of ADHD in adolescents. Adolesc Med. 2002;13:599–624
  37. Greydanus DE. Psychopharmacology of ADHD in adolescents: Quo vadis?. Psychiatr Times. 2003;20:5–9
  38. Greydanus DE, Calles J, Patel DR. Attention deficit hyperactivity disorder. In: Pediatric and Adolescent Psychopharmacology (chapter 4). Cambridge, England: Cambridge University Press; 2007;
  39. Greenhill LL. The science of stimulant abuse. Pediatr Ann. 2006;35(8):552–556
  40. Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry. 1937;94:577–585
  41. Sallee FR, Gill HS. Neuropsychopharmacology III: Psychostimulants. In:  Coffey CE,  Brumback RA editor. Textbook of Pediatric Neuropsychiatry (chapter 52). Washington DC: American Psychiatry Press; 1998;p. 1351–1372
  42. Angold A, Erkanli A, Egger H, et al. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry. 2000;39:975–983
  43. Lefever GB, Dawson KV, Morrow AL. The extent of drug therapy for attention-deficit/hyperactivity disorder among children in public schools. Am J Publ Health. 1999;89:1359–1364
  44. Rowland AS, Umbach DM, Stalone L, et al. Prevalence of medication treatment for attention-deficit/hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health. 2002;92:221–234
  45. Safer DJ, Zito M, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics. 1996;98:1084
  46. Safer DJ, Malever M. Stimulant treatment in Maryland public schools. Pediatrics. 2000;106:533–539
  47. Cox ER, Motheral BR, Henderson RR, et al. Geographic variation in the prevalence ofstimulant medication among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics. 2003;111:237–243
  48. Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth (A 10-year perspective). Arch Pediatr Adolesc Med. 2003;157:17–25
  49. Efron D, Hiscock H, Sewell JR, et al. Prescribing of psychotrophic medications for children by Australian pediatricians and child psychiatrists. Pediatrics. 2003;111:372–375
  50. Rappley MD, Mullen PB, Alvarez FJ, et al. Diagnosis of attention-deficit/hyperactivity disorder an use of psychotropic medication in very young children. Arch Ped Adolesc Med. 1999;153:1039–1045
  51. Rappley MD, Eneli IU, Mullan PB, et al. Patterns of psychotropic medication use in very young children with attention-deficit/hyperactivity disorder. Dev Behav Pediatr. 2002;23:23–30
  52. Zito JM. Five burning questions. Dev Behav Pediatr. 2003;23:S23–S30
  53. Dreyer BP. The diagnosis and management of attention-deficit/hyperactivity disorder in preschool children: the state of our knowledge and practice. Curr Probl Pediatr Adolesc Health Care. 2006;36:3–30
  54. Guevara J, Lozano P, Wickizer T, et al. Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics. 2002;109:733–739
  55. American Academy of PediatricsCommittee on Quality Improvement. Clinical Practice Guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder (Subcommittee on Attention-Deficit/Hyperactivity Disorder). Pediatrics. 2001;108:1033–1044
  56. Clarke SD. ADHD in adolescence. J Adolesc Health. 2000;l27:77–78
  57. Ingram S, Hechtman L, Morgenstern G. Outcomes issues in ADHD-adolescent and adult long-term outcomes. Ment Retard Dev Disabil Res Rev. 1999;5:243–250
  58. Rushton JL, Whitmire JT. Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends, 1992 to 1998. Arch Ped Adolesc Med. 2001;155:560–565
  59. Hechtman L, Weiss G, Perlmanm T. Young adults outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Adolesc Psychiatry. 1984;23:261–269
  60. Solanto MV, Arnsten AFT, Castellanos FX. The neuroscience of stimulant drug action in ADHD. In:  Solanto MV,  Arnsten AFT,  Castellanos FX editor. Stimulant Drugs and ADHD. London: Oxford University Press; 2001;
  61. Gainetdinov RR, Wetsel WC, Jones SR, et al. Role of serotonin in the paradoxical calming effect of psychostimulants in hyperactivity. Science. 1999;283:397–401
  62. Zito J, Safer D, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;283:1025–1030
  63. Ford RE, Greenhill LL, Posner K. Stimulants. In:  Martin A,  Scahill L,  Charney DS, et al. editor. Pediatric Psychopharmacology: Principles and Practice. New York, NY: Oxford University Press; 2003;p. 255–263
  64. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113:762–769
  65. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100:662–666
  66. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry. 1999;38:503–528
  67. Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grow up: replication of psychiatric status. Arch Gen Psychiatry. 1991;48:77–83
  68. Satterfield JH, Cantwell DP, Schell A, et al. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry. 1979;36:212–217
  69. Weiss M, Weiss G. Attention deficit hyperactivity disorder. In:  Lewis M editors. Child and Adolescent Psychiatry: A Comprehensive Textbook. (3rd ed). Philadephia, PA: Lippincott Williams & Wilkins; 2002;p. 645–670
  70. Miller KJ, Castellanos FX. Attention-deficit/hyperactivity disorder. Pediatr Rev. 1998;19:373–384
  71. Kuperman S. Tic disorders in the adolescent. Adolesc Med. 2002;13:537–551
  72. Robertson MM. The Gilles de la Tourette’s syndrome: the current status. Br J Psychiatry. 1989;154:147–169
  73. Varley CK, Vincent J, Varley P, et al. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medication. Compr Psychiatry. 2001;42:228–233
  74. Freeman RD. Attention deficit hyperactivity disorder in the presence of Tourette syndrome. Neurol Clin. 1997;191:411–420
  75. Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev. 2001;22:183–189
  76. Greydanus DE, Van Dyke DH. Neurologic disorders. In:  Greydanus DE,  Patel DR,  Pratt HD editor. Essential Adolescent Medicine. New York, NY: McGraw-Hill Medical Publishers; 2006;p. 235–279
  77. Kuperman S. Tic disorders in children and adolescents. In:  Greydanus DE,  Wolraich ML editor. Behavioral Pediatrics. New York, NY: Springer-Verlag; 1992;p. 451–463
  78. Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medication in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry. 2002;41:26S–49S
  79. Jadad AR, Boyle M, Cunningham C, et al. Treatment of Attention-Deficit/Hyperactivity Disorder (Evidence Report/Technology Assessment No. 11). Rockville, MD: Agency for Healthcare Research and Quality; 1999;AHRQ Publ. No. 00-E005
  80. Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: Effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997;36:589–596
  81. Gadow KD, Nolan EE, Sprafkin J, et al. School observation of children with attention deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr. 1995;16:167–177
  82. Gadow KD, Sverci J, Sprafkin J, et al. Efficacy of methylphenidate for attention deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry. 1995;52:444–455
  83. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999;56:330–336
  84. Law SF, Schachar RJ. Do typical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry. 1999;38:944–951
  85. Jankovic J. Tourette’s syndrome. N Engl J Med. 2001;345:1184–1192
  86. Robertson MM, Eapen V. Pharmacologic controversy of CNS stimulants in Gilles de la Tourette’s syndrome. Clin Neuropharmacol. 1992;15:408–425
  87. McDougle CJ, Goodman WK, Price LH. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry. 1994;55(suppl):24–31
  88. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434–443
  89. Chappell PB, Riddle MA, Schahill L, et al. Guanfacine treatment of comorbid attention-deficit/hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry. 1995;34:1140–1146
  90. Singer HS, Brown J, Quaskey S, et al. The treatment of attention-deficit hyperactivity disorder in Tourette’s syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics. 1995;95:74–81
  91. Steingard R, Biderman J, Spencer T, et al. Comparison of clonidine response in the treatment of attention-deficit hyperactivity disorder with and without comorbid tic disorders. J Amer Acad Child Adolesc Psychiatry. 1993;32:350–353
  92. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:1197
  93. Spencer T, Biederman J, Wilens J. Attention-deficit/hyperactivity disorder and comorbidity. Pediatr Clin North Am. 1999;46:915–927
  94. Anderson VR, Scott LJ. Methylphenidate transdermal system: in attention deficit hyperactivity disorder in children. Drugs. 2006;66(8):1117–1126
  95. McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Dis. 2006;9:476–485
  96. Transdermal methylphenidate (Daytrana) for ADHD. Mett Lett. 2006;48:49–51
  97. López FA. ADHD: new pharmacologic treatments on the horizon. J Dev Behav Pediatr. 2006;27:410–416
  98. Greydanus DE. Psychopharmacology. In:  Hofmann AD,  Greydanus DE editor. Adolescent Medicine. (3rd ed). Stamford, CT: Appleton-Lange; 1997;p. 874–875
  99. Adesman AR. New medications for treatment of children with attention-deficit/hyperactivity disorder (Review and commentary). Pediatr Ann. 2002;31:514–522
  100. Boughton B. Methylphenidate patch effectively treats ADHD. Pediatr News. 2003;37:6
  101. Swanson J. The SNAP Rating Scale (School-Based Assessments and Interventions for ADD Students). Irvine, CA: KC Publishing; 1992;
  102. American Academy of PediatricsCommittee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Practice Guideline (Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder). Pediatrics. 2000;105:1158–1170
  103. Rapoport JL, Buchsbaun MS, Zahn TP, et al. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science. 1978;199:560–563
  104. Pliszka SR, Crismon L, Hughes CW, et al. The Texas Children’s medication algorithm project: revision of the algorithm for pharmacotherapy of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(6):642–657
  105. Davis G, Hendren RL. What pediatricians should know about adolescent psychiatry. Adolesc Med. 1992;3:131–145
  106. Kemph JP, Devane CL, Levin GM, et al. Treatment of aggressive children with clonidine: Results of an open pilot study. J Am Acad Child Adolesc Psychiatry. 1993;32:577–581
  107. Hart-Santora D, Hart LL. Clondine in attention deficit hyperactivity disorder. Ann Pharmacother. 1992;26:37
  108. Silver LB. Alternative (nonstimulant) medications in the treatment of attention-deficit/hyperactivity disorder in children. Pediatr Clin North Am. 1999;46:965–975
  109. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:1551–1559
  110. Prince JB, Wilens TE, Biederman J, et al. Clonidine for sleep disturbances associated with attention-deficit/hyperactivity disorder; a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry. 1996;35:599–605
  111. Pliszka SR. Comparing the effects of stimulant and non-stimulant agents on catecholamine function: Implications for theories of ADHD. In:  Solanto MV,  Arnsten AFT,  Castellanos FX editor. Stimulant Drugs and ADHD. London: Oxford University Press; 2001;p. 332–352
  112. Blackman JA, Fang-Samson L, Gutgesell H. Clonidine and electrocardiograms. Pediatrics. 1996;98:1223
  113. Horrigan JP, Barnhill JL. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol. 1995;5:215–223
  114. Hunt RD, Arnsten AFT, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1995;34:50–54
  115. Scahill L. Guanfacine for attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067–1074
  116. Staufer WB, Greydanus DE. Attention-devicit/hyperactivity disorder psychopharmacology for college students. Pediatr Clin North Am. 2005;52:71–84
  117. Clark HW, Bizzell AC. Federal perspective: the abuse of prescription stimulants. Pediatr Ann. 2006;35(8):595–597
  118. Arria AM, Wish ED. Nonmedical use of prescription stimulants among students. Pediatr Ann. 2006;35(8):557–562
  119. Musser CJ, Ahmann PA, Theye FW, et al. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J Dev Behav Pediatr. 1998;19(3):187–192
  120. McCabe SE, Teter CJ, Boyd CJ. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse. 2004;39(7):1095–1116
  121. Poulin C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ. 2001;165(8):1039–1044
  122. Greydanus DE. Stimulant misuse: strategies to manage a growing problem. Princeton, NJ: ACHA Professional Development Program; 2006;Available at: www.acha.org.
  123. Johnston LD, O’Malley PM, Bachman JG. Monitoring the Future National Survey Results on Drug Use, 1975-2002. II. College Students and Adults Ages 19-40. NIH publication no. 03-5376. Washington DC: US Department of Health and Human Services; 2003;
  124. McCabe SE, Knight JR, Teter CJ. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;100:96–106
  125. Teter CJ, McCabe SE, Cranford JA, et al. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health. 2005;53(6):253–262
  126. Hall KM, Irwin MM, Bowman KA, et al. Illicit use of prescribed stimulant medication among college students. J Am Coll Health. 2005;53(4):167–174
  127. Graff Low K, Gendaszek AE. Illicit use of psychostimulants among college students: a preliminary study. Psychol Health Med. 2002;7:283–287
  128. Upadhyaya HP, Rose K, Wang W, et al. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol. 2005;15(5):799–809
  129. Rimsza ME, Moses KS. Substance abuse on the college campus. Pediatr Clin North Am. 2005;52(I):307–319
  130. Kadison R. Getting an edge: use of stimulants and antidepressants in college. N Engl J Med. 2005;353:1089–1091
  131. Greydanus DE, Patel DR. The adolescent and substance abuse: current concepts. Dis Mon. 2005;51(7):392–431
  132. Greydanus DE, Patel DR. The adolescent and substance abuse: current concepts. Curr Probl Pediatr Adolesc Health Care. 2005;35(3):78–98
  133. Wilford BB, Smith DE, Bucher R. Prescription stimulant sales on the internet. Pediatr Ann. 2006;35(8):575–586
  134. Drug Enforcement Administration (DEA). Yearly Aggregate Production Quotas (1990-2000). Washington DC: Office of Public Affairs, Drug Enforcement Administration; 2002;
  135. Conant-Norville DO, Tofler IR. Attention deficit/hyperactivity disorder and psychopharmacologic treatments in the athlete. Clin Sports Med. 2005;24:829–843
  136. Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol. 2005;15(5):764–776
  137. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? (A meta-analytic review of the literature). Pediatrics. 2003;111(1):179–185
  138. Fischer M, Barkley RA. Childhood stimulant treatment and risk for later substance abuse. J Clin Psychiatry. 2003;64(Suppl 11):19–23
  139. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders?. J Clin Psychiatry. 2003;64(Suppl 11):9–13
  140. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youth with and without ADHD. J Clin Psychiatry. 2003;64(Suppl 11):3–8
  141. Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? (A 13-year prospective study). Pediatrics. 2003;111(1):97–109
  142. Mannuzza S, Klein RG, Moulton JL. Does stimulant treatment place children at risk for adult substance abuse? (A controlled, prospective follow-up study). J Child Adolesc Psychopharmacol. 2003;13(3):273–282
  143. McCabe SE, Boyd CJ. Sources of prescription drugs for illicit use. Addict Behav. 2005;30:1342–1350
  144. Williams RJ, Goodale LA, Shay-Fiddler MA, et al. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. Am J Addict. 2004;13(4):381–389
  145. Murray JB. Psychophysiological aspects of amphetamine-methamphetamine abuse. J Psychol. 1998;132:227–237
  146. Luna GC. Use and abuse of amphetamine-type stimulants in the United States. Pan A J Public Health. 2001;9:114–122
  147. Barrett SP, Darredeau C, Bordy LE, et al. Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry. 2005;50:457–461
  148. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav. 2001;68:611–627
  149. Kapner DA. Infofacts resources: recreational use of Ritalin on college campuses. Available at: http://www.edc.org/hec/pubs/factsheets/ritalin.htm. Accessed September 15, 2005.
  150. Croft HA. Physician handling of prescription stimulants. Pediatr Ann. 2006;35(8):557–562
  151. Schubiner H. Substance abuse in patients with attention-deficit/hyperactivity disorder: therapeutic implications. CNS Drugs. 2005;19(8):643–655
  152. DuPont RL, Bensinger PB. Abuse-resistant drug delivery. Pediatr Ann. 2006;35(8):587–592
  153. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurother. 2005;5:525–539
  154. Barkley RA, Fischer M, Fletcher K, et al. Persistence of attention deficit hyperactivity disorder into adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol. 2002;111:279–289
  155. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry. 2004;65(Suppl 3):27–37
  156. Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. CMAJ. 2003;168(6):715–722
  157. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10 year follow-up study. Psychol Med. 2006;36(2):167–179
  158. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(Suppl 12):10–15
  159. Barkley R. Driving impairment in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27:23–26
  160. Kates N. Attention deficit disorder in adults: management in primary care. Canad Fam Pract. 2005;51:53–59
  161. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:456–463
  162. Connor DF, Glatt SJ, Lopez ID, et al. Psychopharmacology and aggression (I. A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD). J Am Acad Child Adolesc Psychiatry. 2002;41:253–261
  163. Rapport MD, Denny C. Titrating methylphenidate in children with attention-deficit/hyperactivity disorder: is body mass predictive of clinical response?. J Am Acad Child Adolesc Psychiatry. 1997;36:523–530
  164. Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder: an update. Pediatr Rev. 2002;23:234–236
  165. Biederman J, Mick E, Surman E, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829–835
  166. A new long-acting methylphenidate (Concerta). Med Lett. 2000;42:80–81
  167. Swanson JL, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention- deficit/hyperactivity disorder in children. Clin Pharmacol Ther. 1999;66:295–305
  168. Another long-acting methylphenidate (Metadate CD). Med Lett. 2001;43:83–84
  169. Dexmethylphenidate (Focalin) for ADHD. Med Lett. 2002;44:45–46
  170. Johnston C, Fine S. Methods of evaluating methylphenidate in children with attention-deficit hyperactivity disorder: acceptability, satisfaction, and compliance. J Pediatr Psychol. 1993;18:717–730
  171. Barkley RA. A Clinical Workbook, Attention-Deficit Hyperactivity Disorder. (2nd ed). New York, NY: Guilford; 1998;
  172. Markowitz JS. Drug interactions with stimulant medications. Int Clin Psychopharmacol. 1999;14:1–18
  173. Varley C. Sudden death of a child treated with imipramine. J Child Adolesc Psychopharmacol. 2000;10:321–325
  174. Gross-Tsur V, Manor O, van der Meere J, et al. Epilepsy and attention deficit hyperactivity disorder: Is methylphenidate safe and effective?. J Pediatr. 1997;130:670–674
  175. Rappley MD. Safety issues in the use of methylphenidate. Drug Saf. 1997;17:143–148
  176. Nissen SE. ADHD and cardiovascular risk. N Engl J Med. 2006;354:1445–1448
  177. Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: what is a physician to do?. Pediatrics. 2006;118:1215–1219
  178. Anders T, Sharfstein S, Rappley MD, et al. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:2296–2298
  179. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456–463
  180. Generic Drugs. Med Lett. 2002;44:89–90
  181. Adderall and other drugs for attention-deficit/hyperactivity disorder. Med Lett Dr Ther. 1994;36:109–110
  182. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended release inthe treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625–639
  183. Biederman J, Spencer TJ, Wilens TE, et al. Long-term safety and effectiveness of mixed amphetamine salts with extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):16–25
  184. Wilens TE. Bupropion for attention-deficit/hyperactivity disorder. Am J Psychiatry. 2001;158:282–288
  185. Patel DR, Greydanus DE. Office interventions for adolescent smokers. Adolesc Med. 2000;11:577–588
  186. Spencer T, Biederman J, Steingard R, et al. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette’s syndrome. J Am Acad Child Adolesc Psychiatry. 1993;32:211
  187. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry. 2005;66(3):294–299
  188. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112–120
  189. Atomoxetine (Strattera) for ADHD. Med Lett. 2003;45:11–12
  190. Kratochvil CJ, Heiligenstein JH, Dittman R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatr. 2002;41:776–784
  191. Allen AJ, Spencer TJ, Heiligenstein JH, et al. Safety and efficacy of atomoxetine for AHDH in two double-blind, placebo-controlled trials. Biol Psychiatry. 2001;49(suppl 8):32S–33S
  192. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2006;149(1):112–119
  193. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with ADHD: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159:1896–1901
  194. Geller B, Reising D, Leonard HL, et al. Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38:513–516
  195. Prince JB. Nortriptyline in pediatric ADHD. J Child Adolesc Psychopharmacol. 2000;10:193–204
  196. Wilens TE, Biederman J, Mick E, et al. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nervous Mental Dis. 1995;48:183
  197. Brent DA, Birmaher B. Adolescent depression. N Engl J Med. 2002;347:667–671
  198. Harvey A, Preskorn S. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry. 1995;52:783–784
  199. Bartels MG, Varley CK, Metchell J, et al. Pediatric cardiovascular effects of imipramine and desipramine. J Am Acad Child Adolesc Psychiatry. 1991;30:100–103
  200. Varley CK. Anxiety disorders in children and adolescents. Pediatr Clin North Am. 2003;50:530
  201. Varley CK. Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications. Paediatr Drugs. 2001;3:613–627
  202. Sudden death in children treated with a tricyclic antidepressant. Med Lett. 1990;32:53
  203. Varley CK, McClellan J. Case study: two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry. 1997;36:390–394
  204. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention- deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatr. 1996;57:184
  205. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatr. 2002;63(suppl 12):29–35
  206. Chan E, Rappaport LA, Kemper KJ. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr. 2003;24:4–8
  207. Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999;46:977–992
  208. Konofal E, Arnulf I, Lecendreux M, et al. Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome. Pediatr Neurol. 2005;32(5):350–351
  209. Barkley RA. Attention-deficit/hyperactivity disorder. Sci Am. 1998;279(3):66–71
  210. Okie S. ADHD in adults. N Engl J Med. 2006;354(25):2637–2641

PII: S0011-5029(07)00002-8

doi: 10.1016/j.disamonth.2007.01.001

Disease-A-Month
Volume 53, Issue 2 , Pages 70-131 , February 2007

Article Tools